HUTCHMED Completes FDA Submission for High-Potential Colorectal Cancer Drug
HUTCHMED has completed the rolling submission of its New Drug Application to the FDA for fruquintinib, its candidate for refractor metastatic colorectal cancer.
HUTCHMED Completes FDA Submission for High-Potential Colorectal Cancer Drug Read More »
